Abstract
Summary
This article may help people with chronic kidney disease, their families and other caregivers, patient advocates, and healthcare professionals to understand the effects of taking vicadrostat, given with or without empagliflozin, in people with chronic kidney disease.
Chronic kidney disease (or CKD) is a condition where the kidneys are damaged and cannot filter blood properly. The most common causes of CKD are diabetes and hypertension.
CKD varies in its severity and usually gets worse over time. CKD can progress to kidney failure in the most severe cases, although this does not happen in everyone with CKD.
Further information on CKD, its diagnosis, and treatment options are shown below.
National Institute of Diabetes and Digestive and Kidney Diseases (US): https://www.niddk.nih.gov/health-information/kidney-disease/chronic-kidney-disease-ckd
National Institute of Diabetes and Digestive and Kidney Diseases (US; Spanish language): https://www.kidney.org/es/kidney-topics/pruebas-para-revisar-la-salud-renal
National Kidney Foundation (US): https://www.kidney.org/kidney-topics/chronic-kidney-disease-ckd
Kidney Care (UK): https://kidneycareuk.org/kidney-disease-information/kidney-conditions/ckd-chronic-kidney-disease/
Footnotes
Acknowledgements
The authors would like to thank the participants and investigators of this study. The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE) as supported by Good Publication Practice (GPP) guidelines. Debra Brocksmith, MB ChB, PhD, of Envision Ignite, an Envision Medical Communications agency, a part of Envision Pharma Group, provided medical writing support, which was contracted and funded by Boehringer Ingelheim. Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy, as well as intellectual property considerations.
Funding
This study was supported and funded by Boehringer Ingelheim.
Data availability statement
To ensure independent interpretation of clinical study results and enable authors to fulfil their role and obligations under the International Committee of Medical Journal Editors criteria, Boehringer Ingelheim grants all external authors access to relevant clinical study data. In adherence with the Boehringer Ingelheim policy on transparency and publication of clinical study data, scientific and medical researchers can request access to clinical study data, typically, 1 year after the approval has been granted by major regulatory authorities or after termination of the development programme. Researchers should use the https://vivli.org/ link to request access to study data and visit 
for further information.
Conflict of interest statement
P. Rossing has received consultancy and/or speaker’s fees (to his institution) from Abbott, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Gilead, MSD, Novo Nordisk, Sanofi, and Vifor Pharma, and research grants from AstraZeneca, Bayer, and Novo Nordisk. K.R. Tuttle has received research grants from the National Institutes of Health and Travere Therapeutics; and consultancy and/or speaker’s fees from Bayer, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk. J. Meyerhoff, S.V. Shah, and Z. Sun are employees of Boehringer Ingelheim.